71 results
6-K
EX-99.1
BNTX
BioNTech SE
6 May 24
Current report (foreign)
7:18am
by factors including:
severity of the disease under investigation;
complexity and design of the study protocol;
size of the patient population … investigation into these complaints concluded that the reported product quality complaints were due to the combination of a deficient container closure
6-K
EX-99.1
BNTX
BioNTech SE
6 Nov 23
Current report (foreign)
6:54am
by factors including:
severity of the disease under investigation;
complexity and design of the study protocol;
size of the patient population … . A thorough investigation into these complaints concluded that the reported product quality complaints were due to the combination of a deficient container
6-K
EX-99.1
BNTX
BioNTech SE
7 Aug 23
Current report (foreign)
8:02am
trials in a timely manner. Patient and subject enrollment is affected by factors including:
severity of the disease under investigation;
complexity … Kong. A thorough investigation into these complaints concluded that the reported product quality complaints were due to the combination of a deficient
6-K
EX-99.1
BNTX
BioNTech SE
8 May 23
Current report (foreign)
9:22am
by factors including:
severity of the disease under investigation;
complexity and design of the study protocol;
size of the patient population … we received product quality complaints related to our COVID-19 vaccine in Hong Kong. A thorough investigation into these complaints concluded
6-K
EX-99.1
BNTX
BioNTech SE
8 May 23
Current report (foreign)
6:56am
by factors including:
severity of the disease under investigation;
complexity and design of the study protocol;
size of the patient population … received product quality complaints related to our COVID-19 vaccine in Hong Kong. A thorough investigation into these complaints concluded
6-K
EX-99.1
gurklbltj5v0zm8eso4
7 Nov 22
Unaudited Interim Condensed Consolidated Financial Statements
6:24am
20-F/A
xdwrm vrtbwpf
26 Oct 22
Annual report (foreign) (amended)
5:20pm
6-K
EX-99.1
gm8c7t20rpoppj 4n
9 Sep 22
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO
4:41pm
6-K
EX-99.1
n6c2zpbq
8 Aug 22
Unaudited Interim Condensed Consolidated Financial Statements
7:17am
6-K
EX-99.1
sr38m5uy
10 Dec 20
Statement Regarding Cyber Attack on European Medicines Agency
12:00am
6-K
EX-99.1
ihtse91
12 Nov 20
Interim Condensed Consolidated Financial Statements
12:00am